Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT00082823 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2016-06-03
Summary
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
PURPOSE: This phase I trial is studying the side effects of VEGF Trap in treating patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.
Conditions
Interventions
- BIOLOGICAL
-
ziv-aflibercept
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH - lead INDUSTRY
Principal Investigators
-
William P. Tew, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-01-31
- Primary Completion
- 2008-05-31
Countries
- United States
Study Locations
More Related Trials
-
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT06210750 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
NCT05144841 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
NCT00458731 ·Status: COMPLETED ·Phase: PHASE1
-
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
NCT00481832 ·Status: TERMINATED ·Phase: PHASE2
-
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma
NCT00621452 ·Status: COMPLETED ·Phase: PHASE1
-
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
NCT05202782 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
NCT01336920 ·Status: COMPLETED ·Phase: PHASE1
-
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
NCT00644124 ·Status: COMPLETED ·Phase: PHASE1
-
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
NCT04205409 ·Status: COMPLETED ·Phase: PHASE2
-
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
NCT05418088 ·Status: RECRUITING ·Phase: PHASE1
-
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00077155 ·Status: COMPLETED ·Phase: PHASE1
-
Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma
NCT00055640 ·Status: COMPLETED ·Phase: PHASE2
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
NCT03017820 ·Status: RECRUITING ·Phase: PHASE1
-
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
NCT00438802 ·Status: COMPLETED ·Phase: PHASE1
-
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
NCT00101244 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
NCT00005950 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
NCT01258998 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
NCT02082977 ·Status: TERMINATED ·Phase: PHASE1
-
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
NCT00372905 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
NCT00089284 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
NCT00005803 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma
NCT00002501 ·Status: COMPLETED ·Phase: PHASE2
-
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
NCT00074282 ·Status: COMPLETED ·Phase: PHASE2
-
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
NCT00112723 ·Status: TERMINATED ·Phase: PHASE1/PHASE2